Divesiran's Phase 2 data in polycythemia vera will define Silence's survival window before a ~$70M cash position runs dry

Bull

A win would be statistically significant, clinically meaningful reductions in phlebotomy frequency and/or hematocrit control across both the Q6W and Q12W dosing cohorts, extending and confirming the durable efficacy signal seen in Phase 1 where median time to first phlebotomy reached 287 days. Such a result would establish divesiran as a differentiated, infrequently-dosed RNAi therapy in PV, credibly supporting a partnership or licensing deal that relieves cash pressure and funds a Phase 3 program.

Bear

The most likely failure modes are efficacy that does not replicate at scale — particularly if the Q12W dosing interval proves insufficient for sustained hematocrit control — or an adverse event profile that emerges in the larger 48-patient cohort and complicates the benefit-risk narrative. A mixed or inconclusive readout (e.g., one dosing arm meeting endpoints but not the other) would also be damaging, as it would delay and complicate the path to Phase 3 and partnership discussions at a moment when cash reserves are under material pressure.